Skip to main content

Advertisement

SpringerLink
Log in

Cardiovascular risk, hypertension, and NSAIDs

  • Published:
Current Rheumatology Reports Aims and scope Submit manuscript

Abstract

During the past 2 years, a great deal of evaluation has been conducted on the cardiovascular (CV) effects of nonsteroidal anti-inflammatory drugs (NSAIDs) and selective cyclooxygenase (COX)-2 inhibitors. This review focuses on the effects of the NSAIDs and COX-2 inhibitors on blood pressure and CV events. Clinical trial databases for NSAIDs and COX-2 inhibitors have shown varying levels of destabilization of blood pressure control in treated hypertensive patients as well as variable incident rates of the development of arrhythmias, congestive heart failure, myocardial infarction, and stroke. Nonselective and COX-2 selective NSAIDs can be used carefully in arthritis patients with hypertension and stable CV disorders (excluding congestive heart failure and moderate to severe kidney dysfunction) when the individual clinical benefit of anti-inflammatory therapy outweighs the CV and gastrointestinal risk.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Silverstein FE, Faich G, Goldstein JL, et al.: Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. JAMA 2000, 284:1247–1255.

    Article  PubMed  CAS  Google Scholar 

  2. Bombardier C, Laine L, Reicin A, et al.: Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000, 343:1520–1528.

    Article  PubMed  CAS  Google Scholar 

  3. Mukherjee D, Nissen SE, Topol EJ: Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 2001, 286:954–959.

    Article  PubMed  CAS  Google Scholar 

  4. Konstam MA, Weir MR, Reicin A, et al.: Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib. Circulation 2001, 104:2280–2288.

    PubMed  CAS  Google Scholar 

  5. Bresalier RS, Sandler RS, Quan H, et al.: Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005, 352:1092–1102.

    Article  PubMed  CAS  Google Scholar 

  6. Nussmeier NA, Whelton AA, Brown MT, et al.: Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 2005, 352:1081–1091.

    Article  PubMed  CAS  Google Scholar 

  7. Gilroy DW, Colville-Nash PR, Willis D, et al.: Inducible cyclooygenase may have anti-inflammatory properties. Nat Med 1999, 5:698–701.

    Article  PubMed  CAS  Google Scholar 

  8. Kiefer W, Dannhardt G: Novel insights and therapeutic applications in the field of inhibitors of COX-2. Curr Med Chem 2004, 11:3147–3161.

    PubMed  CAS  Google Scholar 

  9. Fosslien E: Biochemistry of cyclooxygenase (COX)-2 inhibitors and molecular pathology of COX-2 in neoplasia. Crit Rev Clin Lab Sci 2000, 37:431–502.

    Article  PubMed  CAS  Google Scholar 

  10. Hao CM, Breyer MD: Hypertension and cyclooxygenase inhibitors. Target: The renal medulla. Hypertension 2004, 44:396–397.

    Article  PubMed  CAS  Google Scholar 

  11. Harris RC, Zhang MZ, Cheng HF: Cyclooxygenase-2 and the renal angiotensin system. Acta Physiol Scand 2004, 181:543–547.

    Article  PubMed  CAS  Google Scholar 

  12. Fries S, Grosser T: The cardiovascular pharmacology of COX-2 inhibition. Hematology Am Soc Hematol Educ Program 2005:445–51.

  13. Rudic RD, Brinster D, Cheng Y, et al.: COX-2-derived prostacyclin modulates vascular remodeling. Circ Res 2005, 96:1240–1247.

    Article  PubMed  CAS  Google Scholar 

  14. Egan KM, Wang M, Lucin MB, et al.: Cyclooxygenases, thromboxane, and atherosclerosis: Plaque destabilization by cyclooxygenase-2 inhibition combined with thromboxane receptor antagonism. Circulation 2005, 111:334–342.

    Article  PubMed  CAS  Google Scholar 

  15. Francois H, Athirakul K, Howell D, et al.: Prostacyclin protects againsts elevated blood pressure and cardiac fibrosis. Cell Metab 2005, 2:201–207.

    Article  PubMed  CAS  Google Scholar 

  16. Rabausch K, Bretschneider E, Sarbia M, et al.: Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2 derived prostaglandins. Circ Res 2005, 96:e1–e6.

    Article  PubMed  CAS  Google Scholar 

  17. Bolli R, Shinmura K, Tang XL: Discovery of a new function of cyclooxygenase (COX)-2: COX-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of pre-conditioning. Cardiovasc Res 2002, 55:506–519.

    Article  PubMed  CAS  Google Scholar 

  18. Antman EM, DeMets D, Loscalzo J: Cyclooxygenase inhibition and CV risk. Circulation 2005, 112:759–770.

    Article  PubMed  CAS  Google Scholar 

  19. Virdis A, Colucci R, Fornai M, et al.: Cyclooxygenase-2 inhibition improves vascular endothelial dysfunction in a rat model of endotoxic shock: Role of inducible nitric-oxide synthase and oxidative stress. J Pharmacol Exp Ther 2005, 312:945–953.

    Article  PubMed  CAS  Google Scholar 

  20. Steffel J, Hermann M, Greutert H, et al.: Celecoxib decreases endothelial tissue factor expression through inhibition of c-Jun terminal NH2 kinase phosphorylation. Circulation 2005, 111:1685–1689.

    Article  PubMed  CAS  Google Scholar 

  21. Sowers JR, White WB, Pitt B, et al.: The effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis and type 2 diabetes. Arch Intern Med 2005, 165:161–168.

    Article  PubMed  CAS  Google Scholar 

  22. Pope JE, Anderson JJ, Felson DT: A meta-analysis of the effects of nonsteroidal anti-inflammatory drugs on blood pressure. Arch Intern Med 1993, 153:477–484.

    Article  PubMed  CAS  Google Scholar 

  23. Johnson AG, Nguyen TV, Day RO: Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med 1994, 121:289–300.

    PubMed  CAS  Google Scholar 

  24. Grover SA, Coupal L, Zowall H: Treating osteoarthritis with cyclooxygenase-2 specific inhibitors: What are the benefits of avoiding blood pressure destabilization? Hypertension 2005, 45:92–97.

    PubMed  CAS  Google Scholar 

  25. White WB: Benefits of antihypertensive therapy in older patients with hypertension. Arch Intern Med 2000, 160:149–150.

    Article  PubMed  CAS  Google Scholar 

  26. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000, 283:1967–1975.

    Article  Google Scholar 

  27. Julius S, Kjeldsen SE, Weber M, et al.: Outcomes in hypertensive patients at high CV risk treated with regimens based on valsart an or amlodipine: the VALUE randomised trial. Lancet 2004, 363:2022–2031.

    Article  PubMed  CAS  Google Scholar 

  28. Morgan TO, Anderson A, Bertram D: Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000, 13:1161–1167.

    Article  PubMed  CAS  Google Scholar 

  29. Schwartz JI, Vandormael K, Malice MP, et al.: Comparison of rofecoxib, celecoxib, and naproxen on renal function in elderly subjects receiving a normal-salt diet. Clin Pharmacol Ther 2002, 72:50–61.

    Article  PubMed  CAS  Google Scholar 

  30. Simon LS, Smolen JS, Abramson SB, et al.: Controversies in COX-2 selective inhibition. J Rheumatol 2002, 29:1501–1510.

    PubMed  CAS  Google Scholar 

  31. Brater DC: Effects of nonsteroidal anti-inflammatory drugs on renal function: focus on cyclooxygenase-2-selective inhibition. Am J Med 1999, 107:65S–70S.

    Article  PubMed  CAS  Google Scholar 

  32. Whelton A, Schulman G, Wallemark C, et al.: Effects of celecoxib and naproxen on renal function in the elderly. Arch Intern Med 2000, 160:1465–1470.

    Article  PubMed  CAS  Google Scholar 

  33. Whelton A, White WB, Bello AE, et al.: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or = 65 years of age with systemic hypertension and osteoarthritis. Am J Cardiol 2002, 90:959–963.

    Article  PubMed  CAS  Google Scholar 

  34. Whelton A: Nephrotoxicity of nonsteroidal anti-inflammatory drugs: physiologic foundations and clinical implications. Am J Med 1999, 106(5B):13S–24S.

    Article  PubMed  CAS  Google Scholar 

  35. Qi Z, Hao CM, Langenbach RI, et al.: Opposite effects of cyclooxygenase-1 and-2 activity on the pressor response to angiotensin II. J Clin Invest 2002, 110:61–69.

    Article  PubMed  CAS  Google Scholar 

  36. Hermann M, Camici G, Fratton A, et al.: Differential effects of selective cyclooxygenase-2 inhibitors on endothelial function in salt-induced hypertension. Circulation 2003, 108:2308–2311.

    Article  PubMed  CAS  Google Scholar 

  37. Hermann M, Shaw S, Kiss E, et al.: Selective COX-2 inhibitors and renal injury in salt-sensitive hypertension. Hypertension 2005, 45:193–197.

    Article  PubMed  CAS  Google Scholar 

  38. Hinz B, Dormann H, Brune K: More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum 2006, 54:282–291.

    Article  PubMed  CAS  Google Scholar 

  39. Winner LK, Elliot DJ, Miners JO, Knights KM: In vitro glucoronidation of aldosterone by human liver and kidney cortical microsomes and recombinant UDP-glucuronosyltransferase (UCT) 287: inhibition by non-steroidal anti-inflammatory drugs (NSAIDs). Proc Aust Soc Clin Exp Pharmacol Toxicol 2005, 11:P2–02.

    Google Scholar 

  40. Knights KM, Mangoni AA, Minors JO: Non-selective nonsteroidal anti-inflammatory drugs and cardiovascular events: is aldosterone the silent partner in crime? Br J Clin Pharmacol 2006, 61:738–740.

    Article  PubMed  CAS  Google Scholar 

  41. White WB, Kent J, Taylor A, et al.: Effects of celecoxib on ambulatory blood pressure in hypertensive patients on ACE inhibitors. Hypertension 2002, 39:929–934.

    Article  PubMed  CAS  Google Scholar 

  42. Izhar M, Alausa T, Folker A, et al.: Effects of COX-inhibition on blood pressure and kidney function in ACE inhibitor-treated blacks and hispanics. Hypertension 2004, 43:574–577.

    Article  Google Scholar 

  43. Houston MC, Weir M, Gray J, et al.: The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995, 155:1049–1054.

    Article  PubMed  CAS  Google Scholar 

  44. Mamdani M, Juurlink DN, Lee DS, et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet 2004, 363:1751–1756.

    Article  PubMed  CAS  Google Scholar 

  45. White WB, Faich G, Whelton A, et al.: Comparison of thromboembolic events in patients treated with celecoxib, a cyclooxygenase-2 specific inhibitor, versus ibuprofen or diclofenac. Am J Cardiol 2002, 89:425–430.

    Article  PubMed  CAS  Google Scholar 

  46. White WB, Faich G, Borer JS, Makuch RW: CV thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 2003, 92:411–418.

    Article  PubMed  CAS  Google Scholar 

  47. White WB, West CR, Borer JS, et al.: Risk of CV events in patients receiving celecoxib. A metanalysis of randomized clinical trials. Am J Cardiol 2006, in press.

  48. Collaborative overview of randomized trials of antiplatelet therapy: I: prevention of death, myocardial infarction, and stroke. Antiplatelet Trialists’ Collaboration. BMJ 1994, 308:81–106.

    Google Scholar 

  49. Farkouh ME, Kirshner H, Harrington RA, et al.: Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 2004, 364:675–684.

    Article  PubMed  CAS  Google Scholar 

  50. Graham DJ, Campen D, Hui R, et al.: Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 2005, 365:475–481.

    PubMed  CAS  Google Scholar 

  51. Gislason GH, Jacobsen S, Rasmussen JN, et al.: Risk of death or reinfarction associated with the use of selective cyclooxygenase-2 inhibitors and nonselective non-steroidal antiinflammatory drugs after acute infarction. Circulation 2006, 113:2906–2913.

    Article  PubMed  CAS  Google Scholar 

  52. McGettigan P, Henry D: Cardiovascular risk and inhibition of cyclooxygenases: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase-2. JAMA 2006, 296:1633–1644.

    Article  PubMed  CAS  Google Scholar 

  53. Chan AT, Manson JE, Albert CM, et al.: Nonsteroidal antiinflammatory drugs, acetaminophen, and the risk of cardiovascular events. Circulation 2006, 113:1578–1587.

    Article  PubMed  CAS  Google Scholar 

  54. Solomon SD, McMurray JJ, Pfeffer MA, et al.: Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005, 352:1071–1080.

    Article  PubMed  CAS  Google Scholar 

  55. Bertagnolli MM, Eagle CJ, Zauber AG, et al.: Celecoxib for the prevention of colorectal adenomas. N Engl J Med 2006, 355:873–884.

    Article  PubMed  CAS  Google Scholar 

  56. Arber N, Eagle CJ, Spicak J, et al.: Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006, 355:885–895.

    Article  PubMed  CAS  Google Scholar 

  57. Singh G, Mithal A, Triadafilopoulos G: Both selective COX-2 inhibitors and non-selective NSAIDs increase the risk of acute myocardial infarction in patients with arthritis: selectivity is with the patient not the drug class. Ann Rheum Dis 2005, 64(Suppl III):85.

    Google Scholar 

  58. Sturkenboom MC, Dieleman J, Verhamme K, et al.: Cardiovascular events during use of COX-2 selective and non-selective NSAIDs. Pharmacoepidemiol Drug Saf 2005, 14:S57.

    Google Scholar 

  59. Hippisley-Cox J, Coupland C: Risk of myocardial infarction in patients taking cyclooxygenase inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ 2005, 330:1366–1372.

    Article  PubMed  CAS  Google Scholar 

  60. Johnsen SP, Larsson H, Tarone RE, et al.: Risk of hospitalisation for myocardial infarction among users of rofecoxib, celecoxib and other NSAIDs: a population based case control study. Arch Intern Med 2005, 165:978–984.

    Article  PubMed  CAS  Google Scholar 

  61. Levesque LE, Brophy JM, Zhang B: The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med 2005, 142:481–489.

    PubMed  CAS  Google Scholar 

  62. Kimmel SE, Berlin JA, Reilly M, et al.: The effects of non-selective non-aspirin non-steroidal anti-inflammatory medications on the risk of non-fatal myocardial infarction and their interaction with aspirin. J Am Coll Cardiol 2004, 43:985–990.

    Article  PubMed  CAS  Google Scholar 

  63. Kimmel SE, Berlin JA, Reilly M, et al.: Patients exposed to rofecoxib and celecoxib have different odds of nonfatal myocardial infarction. Ann Intern Med 2005, 142:157–164.

    PubMed  CAS  Google Scholar 

  64. Ray WA, Stein CM, Daugherty JR, et al.: Cyclo-oxygenase-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 2002, 360:1071–1073.

    Article  PubMed  CAS  Google Scholar 

  65. Ray WA, Stein CM, Hall K, et al.: Non-steroidal anti-inflammatory drugs and the risk of serious coronary heart disease: an observational cohort study. Lancet 2002, 359:118–123.

    Article  PubMed  CAS  Google Scholar 

  66. Fischer LM, Schlienger RG, Matter CM, et al.: Discontinuation of non-steroidal anti-inflammatory drug therapy and the risk of acute myocardial infarction. Arch Intern Med 2004, 164:2472–2476.

    Article  PubMed  CAS  Google Scholar 

  67. Garcia Rodriguez LA, Gonzalez-Perez A: Long-term use of traditional of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med 2005, 3:17.

    Article  PubMed  Google Scholar 

  68. Bak S, Andersen M, Tsiropoulos I, et al.: Risk of stroke associated with non-steroidal anti-inflammatory drugs. Stroke 2003, 34:379–386.

    Article  PubMed  CAS  Google Scholar 

  69. Solomon DH, Glynn RJ, Levin R, Avorn J: Non-steroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099–1104.

    Article  PubMed  CAS  Google Scholar 

  70. Schlienger RG, Jick H, Meier CR: Use of nonsteroidal anti-inflammatory drugs and the risk of first-time acute myocardial infarction. Br J Clin Pharmacol 2002, 54:327–332.

    Article  PubMed  CAS  Google Scholar 

  71. Watson DJ, Rhodes T, Cai B, Guess HA: Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105–1110.

    Article  PubMed  CAS  Google Scholar 

  72. MacDonald TM, Wei L: Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361:573–574.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Hypertension and Clinical Pharmacology, Pat and Jim Calhoun Cardiology Center, University of Connecticut School of Medicine, 263 Farmington Avenue, Farmington, CT, 06030-3940, USA

    William B. White MD

Authors
  1. William B. White MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to William B. White MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

White, W.B. Cardiovascular risk, hypertension, and NSAIDs. Curr Rheumatol Rep 9, 36–43 (2007). https://doi.org/10.1007/s11926-007-0020-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11926-007-0020-3

Keywords

Search

Navigation